Lunai Bioworks Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 27, 2026 (with events reported through May 1, 2026), details a material definitive agreement and the subsequent completion of an asset acquisition by Lunai Bioworks Inc. (LNAI). The filing addresses the company's ongoing efforts to regain compliance with Nasdaq listing standards regarding stockholders' equity and bid price.
Key Financial Metrics and Transaction Details
The filing does not report traditional operating metrics such as revenue, profit, or cash flow for the period, as the acquired entity had no operations. Key transaction metrics include:
- Transaction Type: Triangular merger to acquire a multi-jurisdictional patent portfolio.
- Consideration: Issuance of 8 shares of Series B Convertible Preferred Stock with an aggregate Stated Value of $20,000,000.
- Allocation: $12,500,000 to Oncotelic Inc. (62.5%) and $7,500,000 to Pelerin Therapeutics Inc. (37.5%).
- Cash Impact: No cash consideration was paid.
- Debt and Liabilities: The acquired entity had no material liabilities; the Company assumed no material liabilities.
- Liquidity/Equity: The transaction is intended to increase stockholders' equity to exceed the $2.5 million minimum required by Nasdaq Listing Rule 5550(b)(1).
Material Changes Versus Prior Period
The primary material change is the acquisition of intellectual property assets previously held by Neurobridge IP Holdings Incorporated. Unlike a standard business acquisition, the target entity had no employees, customers, revenue, or operating infrastructure. The sole assets transferred were patent applications and granted patents related to Alzheimer's disease and neurological disorders. Consequently, no historical financial statements or pro forma information were required.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Compliance: The Company believes the issuance of the Series B Preferred Stock satisfies the Nasdaq Stockholders' Equity Rule, pending formal determination by the Nasdaq Hearings Panel. However, the transaction does not cure the $1.00 minimum bid price requirement. A reverse stock split proposal remains on the ballot for a special meeting on May 8, 2026, to address the bid price rule.
Security Terms: The Series B Preferred Stock is convertible into common stock at a fixed price of $1.50 per share (maximum 13,333,333 shares) but is subject to a "Conversion Gate" requiring stockholder approval under Nasdaq Rule 5635. The Company covenanted to seek this approval within 180 days of the merger closing.
Risks and Contingencies:
- Delisting Risk: There is no assurance the Nasdaq Panel will accept the transaction as sufficient for equity compliance or that the reverse split will cure the bid price deficiency.
- Accounting Treatment: The equity value recognized for Nasdaq compliance depends on the final accounting classification and fair-value analysis of the preferred stock.
- IP Clawback: The agreement includes a "clawback" provision allowing the Company to forfeit or cancel shares if the acquired patents are found invalid or unenforceable.
- Commercial Viability: The acquired patents are not associated with ongoing operations, and their commercial value is uncertain.
Investor Verification Checklist
- Verify the Nasdaq Hearings Panel's formal determination regarding compliance with the Stockholders' Equity Rule following the May 1, 2026 issuance.
- Confirm the outcome of the Special Meeting on May 8, 2026, specifically the approval of the reverse stock split to address the Bid Price Rule.
- Review the final accounting treatment of the Series B Preferred Stock to ensure the $20 million Stated Value is recognized as equity for listing purposes.
- Monitor the timeline for the submission of the Stockholder Approval Proposal required to enable conversion of the Series B Preferred Stock.
- Assess the validity and enforceability status of the acquired Pelerin and Oncotelic patent families.